
Assessing the generalizability of finerenone trial criteria to a British Columbia population with type 2 diabetes in a community endocrinology setting
Considering the substantial health care burden of end-stage renal disease, integrating therapies like finerenone that reduce renal risk is essential, especially in populations with a higher prevalence of pre-existing cardiovascular disease. Read More











